1. Home
  2. IMNN vs SPHL Comparison

IMNN vs SPHL Comparison

Compare IMNN & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imunon Inc.

IMNN

Imunon Inc.

N/A

Current Price

$1.04

Market Cap

7.9M

Sector

Health Care

ML Signal

N/A

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$2.30

Market Cap

7.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNN
SPHL
Founded
1982
2002
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.1M
IPO Year
2000
2023

Fundamental Metrics

Financial Performance
Metric
IMNN
SPHL
Price
$1.04
$2.30
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $17.00
N/A
AVG Volume (30 Days)
155.3K
★ 203.5K
Earning Date
11-12-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.36
52 Week High
$5.29
$25.11

Technical Indicators

Market Signals
Indicator
IMNN
SPHL
Relative Strength Index (RSI) 25.66 45.09
Support Level N/A N/A
Resistance Level $1.59 $3.17
Average True Range (ATR) 0.12 0.26
MACD -0.03 -0.02
Stochastic Oscillator 15.87 8.72

Price Performance

Historical Comparison
IMNN
SPHL

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: